within Pharmacolibrary.Drugs.ATC.L;

model L01EB11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.81,
    Cl             = 19.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 110 / 1000000,
    adminCount     = 1,
    Vd             = 0.306,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.012,
    Tlag           = 10.799999999999999
  );

  annotation(Documentation(
    info ="<html><body><p>Aumolertinib is a third-generation, oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). It is approved in China for the treatment of patients with advanced or metastatic NSCLC harboring EGFR mutations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced NSCLC following oral administration. Population PK analyses and clinical studies support the following estimates.</p><h4>References</h4><ol><li><p>Ji, W, et al., &amp; Zhang, X (2022). Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants. <i>Clinical pharmacology in drug development</i> 11(9) 1046â€“1053. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1095&quot;>10.1002/cpdd.1095</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35437951/&quot;>https://pubmed.ncbi.nlm.nih.gov/35437951</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EB11;
